Biotechnology is moving into a more commercially significant phase as scientific advances become easier to develop, manufacture and deliver. Progress in cell and gene therapy, artificial intelligence, drug delivery and clinical development is widening the range of diseases that can be treated and improving the potential economics of new medicines.
Cell and gene therapies remain one of the clearest areas of change. These technologies are moving beyond highly experimental applications and towards broader clinical use. Improvements in manufacturing, delivery and treatment design are making them more practical, particularly in cancer, rare diseases and genetic disorders.
Some therapies aim to deliver a major benefit through a single treatment rather than ongoing medication. That can create substantial clinical and commercial value where outcomes are strong. The main constraints remain cost, manufacturing complexity and patient access, but continued improvements could allow successful therapies to reach larger populations.
The opportunity is also expanding through the wider use of existing medicines. Treatments developed for one condition can sometimes be applied to additional diseases, extending their commercial potential and reducing reliance on a single indication.
GLP-1 medicines are a clear example. Their use has expanded beyond diabetes into obesity and other cardiometabolic conditions. Oral versions could broaden access further by offering an alternative to injectable treatments. This type of expansion can increase the value of a successful drug platform and extend its commercial life.
Clinical development is also becoming more efficient. Better trial design, improved data analysis and more targeted patient selection can help companies make decisions earlier and allocate capital more effectively. Faster regulatory pathways in areas of high unmet medical need can also reduce the time required to reach important milestones.
AI is being used to identify drug targets, design molecules, analyse clinical data and support trial development. Its value will depend on results rather than adoption alone, but the potential impact is important. Better tools could reduce research costs, shorten parts of the development process and improve the probability of selecting stronger drug candidates.
Drug delivery is another area with direct commercial relevance. More precise technologies can help medicines reach specific tissues while limiting exposure elsewhere in the body. This can improve effectiveness and reduce side effects, particularly in areas such as oncology.
Antibody-drug conjugates, radioligand therapies and RNA-based treatments are examples of technologies supporting this shift towards precision medicine. Better delivery can also make previously difficult therapeutic approaches more viable, expanding the number of potential drug programmes.
The broader biotechnology story is therefore becoming less dependent on scientific discovery alone. The ability to manufacture treatments efficiently, move through clinical development, secure regulatory approval and reach patients is becoming just as important.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
